IFNα-induced recurrence of graves' disease ten years after thyroidectomy in chronic viral hepatitis C. Case report

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 4, 2008, Pages 453-456

  Duncea, Ileana ^a,b   Pepene, Carmen E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Endocrinology Clinic   (Romania)

Author keywords

Alpha IFN; Autoimmune thyroid disease; Chronic hepatitis C; Radioiodine therapy

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; LEVOTHYROXINE; RADIOACTIVE IODINE; RIBAVIRIN; THIAMAZOLE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; ANTIVIRUS AGENT;

ADULT; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; BONE MASS; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FREE THYROXINE INDEX; GRAVES DISEASE; HEPATITIS C; HUMAN; INSOMNIA; LIVER FUNCTION; MALE; NERVOUSNESS; RADIOIODINATION; RECURRENT DISEASE; SECONDARY OSTEOPOROSIS; SIDE EFFECT; SWEATING; TACHYCARDIA; THYROID WEIGHT; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREMOR; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GRAVES DISEASE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN; THYROXINE;

EID: 67049174155     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ţǎrmure S, Grigorescu M, Cristea A, et al. Boala celiacǎ la pacienţii cu afecţiuni tiroidiene autoimune: studiu clinic, serologic si histologic. Clujul Medical 2003; 76: 601-607.
2. Ch'ng CL, Biswas M, Benton A, Jones MK, Kingham JG. Prospective screening for celiac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol 2005; 62: 303-306.
3. Hadithi M, de Boer H, Meijer JW, et al. Coeliac disease in Dutch patients with Hashimoto's thyroiditis and vice versa. World J Gastroenterol 2007; 13: 1715-1722.
4. Shah SA, Peppercorn MA, Pallotta JA. Autoimmune (Hashimoto's) thyroiditis associated with Crohn's disease. J Clin Gastroenterol 1998; 26: 117-120.
5. Inokuchi T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ka T, Yamamoto T. Autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in two patients with Crohn's disease: case reports and literature review. Intern Med 2005; 44: 303-306.
6. Bonapace ES, Srinivasan R. Simultaneous occurrence of inflammatory bowel disease and thyroid disease. Am J Gastroenterol 2001; 96: 1925-1926.
7. Horita M, Takahashi N, Seike M, Nasu S, Takaki R. A case of primary biliary cirrhosis associated with Hashimoto's thyroiditis, sclerodermia and Sjogren's syndrome. Intern Med 1992; 31: 418-421.
8. Nishio A, Keeffe EB, Ishibashi H, Gershwin EM. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Monit 2000; 6: 181-193.
9. Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophtalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004; 14: 631-634.
10. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-13.
11. Testa A, Castaldi P, Fant V, Fiore GF, Grieco V, De Rosa A, Pazardjiklian MG, De Rosa G. Prevalence of HCV antibodies in autoimmune thyroid disease. Eur Rev Med Pharmacol Sci 2006; 10: 183-186.
12. Bhakri H, Sriskandan K, Davis T, Pettingale K, Tee D. Recombinant gamma IFN and autoimmune thyroid disease. Lancet 1985; 24: 457
13. Moncoucy X, Leymarie F, Delemer B, et al. Risk factors and longterm course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005; 29: 339-345.
14. Georgescu C. Osteoporoza - fiziopatologie, diagnostic, tratament. [Osteoporosis - physiopathology, diagnosis and therapy]. Cluj-Napoca, Risoprint; 2005
15. Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing IFN-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005; 90: 4133-4137.
16. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral heptatitis and their relationship to IFN alfa therapy. Hepatology 1997; 26: 206-210.
17. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of IFN-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672.
18. Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (IFN plus ribavirin) for hepatitis C virus. J Viral Hepat 2000; 7: 393-395
19. Bohbot NL, Young J, Orgiazzi J, et al. IFN-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 2006; 154: 367-372.
20. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of IFN-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86: 1925-1929.
21. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by IFN alpha therapy for chronic hepatitis C. Gut 2001; 48: 378-383.
22. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultanous development of diabetic ketoacidosis and hashitoxicosis in a patient treated with pegylated IFN-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13: 1292-1294.
23. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843-1847.
24. Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha IFN in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 812-817.
25. Moreira RO, Balduino A, Martins HS, Reis JS, Duarte MF, Farias ML, Borojevic R. Ribavirin, but not IFN alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2004; 75: 160-168.
26. Kaser A, Enrich B, Ludwiczek O, Vogel W, Tilg H. IFN-alpha (-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection by the perforin pathway. Clin Exp Immunol 1999; 118(1): 71-77.
27. Wang SH, Bretz JD, Phelps E, Mezosi E, Arscott PL, Utsugi S, Baker JR Jr. A unique combination of inflammatory cyotkines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol 2002; 168: 2470-2474.
28. Duncea I. Ficatul în patologia endocrinǎ. In: Grigorescu M. Tratat de Hepatologie. 1st Edn, Editura Medicalǎ Naţionalǎ, Bucureşti, 2004, 957-970.
29. Yamazaki K, Kanaji Y, Shizume K, Yamakawa Y, Demura H, Kanaji Y, Obara T et al. Reversible inhibition by IFNs and ß of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab 1993; 77: 1439-1441.
30. Caraccio N, Giannini R, Cuccato S, et al. Type I IFNs modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005; 90: 1156-1162.
31. Tedelind S, Ericson LE, Karlsson JO, Nilsson M. IFN-gamma down-regulated claudin-1 and impairs the epithelial barrier function in primary cultured human thyrocytes. Eur J Endocrinol 2003; 149: 215-221.
32. Minelli R, Girasole G, Pedrazzoni M, et al. Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human IFN alpha therapy. J Invest Med 1996; 44: 370-374.
33. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: IFN-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89: 3656-3661.
34. Wada M, Hiraizumi W, Fujimoto M, et al. Occurrence of Graves' disease during retreatment with IFN-alpha2a for chronic hepatitis C. Intern Med 1995; 34: 1097-1100.